Sukumar Nagendran - Dec 14, 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: President and Head of R&D, Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Stock symbol: TSHA
Transactions as of: Dec 14, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/18/2023, 04:47 PM
Previous filing: Jun 8, 2023
Next filing: Jan 4, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+334K		$0.00	334K	Dec 14, 2023	Common Stock	334K	$0.70	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Content

The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.